



## **FOR IMMEDIATE RELEASE**

### **Molecular Targeting Technologies, Inc. Announces Closing of Series A Financing to Develop Novel Neuroendocrine Neoplasm Drug**

West Chester, Pa, June 18, 2019---Molecular Targeting Technologies, Inc. (MTTI) announced today that MTT Holding Company will finance clinical development of <sup>177</sup>Lu-DOTA-EB-TATE (EBTATE), a novel drug, targeting tumors in Somatostatin Receptor Positive (SSTR2+) Neuroendocrine Neoplasms (NENs) patients, a market projected to be near \$1.5B by 2027.

Lutathera®, an approved radiotherapeutic for NENs clears rapidly from the body and requires repeat dosing for efficacy. MTTI's innovative EBTATE technology overcomes this deficiency. It incorporates truncated Evans Blue which binds to albumin, slowing clearance. This enables lower, less frequent dosing of the radiotherapy to provide a therapeutic benefit with less toxicity.

Ji Li, Manager of Conway Capital USA commented, "We're proud to lead this investment. In its early human studies, EBTATE has already proven to be a game changer in NEN treatment and we expect positive outcomes as we progress to later clinical trials."

Zhaohui Zhu, MD, Ph.D., of the Peking Union Medical College Hospital, Chinese Academy of Medical Sciences who performed the clinical study added, "EBTATE showed remarkably higher uptake and retention in NENs," and "our first-in-human studies<sup>1,2</sup> demonstrated a single low-dose EBTATE treatment appears to be safe and effective in the treatment of NENs."

"We're optimistic about accelerating clinical translation of this robust molecule to drive better patient outcomes," said Chris Pak, President & CEO of MTTI.

MTTI is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of disease. More information: [www.mtarget.com](http://www.mtarget.com).

<sup>1</sup> Safety, Pharmacokinetics and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analogue <sup>177</sup>Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. Journal of Nuclear Medicine, published on April 13, 2018 as doi:10.2967/jnumed.118.209841

<sup>2</sup> Response to Single Low-dose <sup>177</sup>Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. Theranostics 2018; 8(12): 3308-3316. doi: 10.7150/thno.25919

Contact: Chris Pak, Email: [cpak@mtarget.com](mailto:cpak@mtarget.com)